Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins

AstraZeneca602 enrolled

Overview

To estimate the rates of percutaneous coronary intervention (PCI) outcomes in patients after drug-eluting stents implantation who take statins.

Study Type

OBSERVATIONAL

Enrollment

602

Conditions

Dyslipidemia Coronary Heart Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stable angina with indication to PCI * Hospitalization to Russian Cardiological Research Center (РКНПК) for PCI procedure with drug-eluting stents implantation * Statin therapy initiated for at least one month prior to PCI * Written informed consent provided prior the start of participation in the study. Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. * Presence of ACS during the current hospitalization * Severe CHF (NYHA III/IV) or LVEF\<40 % * Stroke within 6 months before PCI * Acute or chronic inflammatory disease * Anti-inflammatory medications intake, with the exception of aspirin * Severe liver or muscle disease * Severe kidney disease / renal failure with creatinine \> 3 mg/dl * History of oncologic disease * Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Locations (1)

Research Site

Moscow, Russia

Outcomes

Primary Outcomes

To estimate the rates of percutaneous coronary intervention (PCI) outcomes in patients after drug-eluting stents implantation who take statins.

Time frame: 3 visits for 12 month (before and after PCI)

Secondary Outcomes

To evaluate prognostic factors (demographic, co-morbidity, smoking, LDL-C, inflammatory and cardiac markers) in patients undergoing PCI with drug eluting stent (DES) implantation who take statins and their association with PCI (MACCE) outcomes

Time frame: 3 visits for 12 month

To estimate Low Density Lipoprotein Cholesterol (LDL-C) target level achievement and lipid-lowering therapy details in patients taking standard lipid lowering therapy prior the PCI.